BioNTech Surpasses Q4 Revenue Estimates
BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.
Biopharmaceutical company BioNTech SE (NASDAQ:BNTX) reported fourth-quarter and full-year 2024 earnings on Monday, March 10, that topped analysts' consensus expectations. It reported revenue of 1.19 billion euros, ahead of estimates for 1.14 billion but down nearly 43% from the prior year's quarter. Earnings per share (EPS) stood at 1.08 euros against the expected 0.42 euros, a significant outperformance.
This quarter displayed resilience, focusing on R&D expansion, primarily in oncology, while navigating reduced COVID-19 vaccine demand and legal challenges.
Source: BioNTech. Note: Analysts' consensus estimates for the quarter provided by FactSet. YOY = Year over year.
